A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion [4]

Rheumatology

Volumn 43, Issue 11, 2004, Pages 1450-1451

  Mavragani, C P ^b   Vlachoyiannopoulos, P G ^b   Kosmas, N ^b   Boletis, I ^a   Tzioufas, A G ^b   Voulgarelis, M ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HYPERTENSIVE AGENT; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; ARTHRALGIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HEADACHE; HUMAN; LETTER; LEUKOENCEPHALOPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL IMPAIRMENT;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPERTENSIVE ENCEPHALOPATHY; LUPUS NEPHRITIS; SYNDROME;

EID: 8344240465     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh305     Document Type: Letter

References (12)

1. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
2. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90: 2188-95.
3. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
4. Gimenez-Mesa E, Martinez-Salio A, Porta-Etessam J et al. [Reversible posterior leukoencephalopathy in a patient with non-Hodgkin's lymphoma after treatment with CHOP]. An Med Intern 2001;18:591-3.
5. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 2001;24:361-4.
6. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003;12:798-800.
7. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
8. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70.
9. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol 1993;71:571-81.
10. Moreau T, Coles A, Wing M et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-37.
11. White RP, Abraham S, Singhal S, Manji H, Clarke CR. Progressive multifocal leukoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus. Rheumatology 2002; 41:826-7.
12. Primavera A, Audenino D, Mavilio N, Cocito L. Reversible posterior leukoencephalopathy syndrome in systemic lupus and vasculitis. Ann Rheum Dis 2001;60:534-7.